Investment Analysts’ updated eps estimates for Tuesday, August 29th:
Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
Akari Therapeutics PLC (NASDAQ:AKTX) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $4.00 target price on the stock. According to Zacks, “Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company’s lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. “
AU Optronics Corp (NYSE:AUO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Au Optronics is a world-leading manufacturer of large-size thin film transistor liquid crystal display panels, which are currently the most widely used flat panel display technology. They are used in notebook computers, desktop monitors, televisions, digital cameras, DVD players, PDAs, mobile phones, portable games, and car navigation systems, among other applications. “
Bankinter SA (OTCMKTS:BKNIY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $11.00 target price on the stock. According to Zacks, “Bankinter is in the financial services industry. They are a banking entity subject to the supervision of the Bank of Spain and the Spanish National Securities Market Commission. Their products range from: Current Accounts, Term Deposits, Investment Funds, Pension Plans, Model Portfolios,Insurance Credit and Debit Cards, Assets (Mortgage and pledged loans) and Deposits of Securities. “
Bellerophon Therapeutics (NASDAQ:BLPH) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $1.25 target price on the stock. According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “
Cameco Corporation (NYSE:CCJ) (TSE:CCO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Cameco Corporation is one of the world’s largest uranium producers, a significant supplier of conversion services and one of two CANDU fuel manufacturers in Canada. Their competitive position is based on their controlling ownership of the world’s largest high-grade reserves and low-cost operations. Their uranium products are used to generate clean electricity in nuclear power plants around the world. They also explore for uranium in the Americas, Australia and Asia. Their shares trade on the Toronto and New York stock exchanges. Their head office is in Saskatoon, Saskatchewan. “
Edap Tms (NASDAQ:EDAP) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
Edge Therapeutics (NASDAQ:EDGE) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Edge Therapeutics, Inc. is a biotechnology company which discovers, develops and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate which are in preclinical trial EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage, EG-1964, to prevent recurrent bleeding after treatment for cSDH and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. is headquartered in Berkeley Heights, New Jersey. “
NIC (NASDAQ:EGOV) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “NIC Inc. is a provider of Internet-based, electronic government services that help governments use the Internet to reduce costs and provide a higher level of service to businesses and citizens. They accomplish this currently through three different business segments: state and local portal businesses, government procurement business and eGovernment products businesses. “
Enquest PLC (NASDAQ:ENQUF) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Enquest PLC is an oil and gas development and production company. It focuses on oil and oil linked hydrocarbons. Enquest PLC is based in London, the United Kingdom. “
Eco-Stim Energy Solutions (NASDAQ:ESES) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Eco-Stim Energy Solutions, Inc. is an oilfield service and technology company. The company provides management technologies, well stimulation and completion services to oil and gas producers. Eco-Stim Energy Solutions, Inc. is based in Houston, Texas. “
East West Bancorp (NASDAQ:EWBC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “East West Bancorp, Inc. is the holding company for East West Bank, East West Capital Trust I, East West Capital Trust II and Risk Services, Inc. “
